Cytomx Therapeutics Stock Today
| CTMX Stock | USD 1.76 0.10 5.38% |
Performance4 of 100
| Odds Of DistressLess than 37
|
CytomX Therapeutics is trading at 1.76 as of the 17th of April 2024; that is -5.38 percent down since the beginning of the trading day. The stock's open price was 1.86. CytomX Therapeutics has about a 37 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for CytomX Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of February 2024 and ending today, the 17th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of October 2015 | Category Healthcare | Classification Health Care |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 67.73 M outstanding shares of which 3.32 M shares are currently shorted by private and institutional investors with about 2.17 trading days to cover. More on CytomX Therapeutics
Moving together with CytomX Stock
| 0.8 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
| 0.68 | BMY | Bristol Myers Squibb Earnings Call Next Week | PairCorr |
Moving against CytomX Stock
| 0.67 | AMGN | Amgen Inc Financial Report 25th of April 2024 | PairCorr |
| 0.56 | BIIB | Biogen Inc Earnings Call This Week | PairCorr |
| 0.47 | ABVC | ABVC Biopharma | PairCorr |
| 0.43 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
CytomX Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. CytomX Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding CytomX Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Sean McCarthy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, NASDAQ Composite Total, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering CytomX Therapeutics report their recommendations after researching CytomX Therapeutics' financial statements, talking to executives and customers, or listening in on CytomX Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering CytomX Therapeutics. The CytomX consensus assessment is calculated by taking the average forecast from all of the analysts covering CytomX Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to CytomX Therapeutics' liquidity, profitability, solvency, and operating efficiency, CytomX Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of CytomX Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CytomX Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to CytomX Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CytomX Therapeutics' financial leverage. It provides some insight into what part of CytomX Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CytomX Therapeutics (CTMX) is traded on NASDAQ Exchange in USA. It is located in 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 120 people. CytomX Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 133.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CytomX Therapeutics's market, we take the total number of its shares issued and multiply it by CytomX Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. CytomX Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 67.73 M outstanding shares of which 3.32 M shares are currently shorted by private and institutional investors with about 2.17 trading days to cover.
CytomX Therapeutics currently holds about 194.29 M in cash with (56.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check CytomX Therapeutics Probability Of Bankruptcy
Ownership AllocationCytomX Therapeutics holds a total of 67.73 Million outstanding shares. 30% of CytomX Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CytomX Ownership Details
CytomX Stock Price Odds Analysis
Based on a normal probability distribution, the odds of CytomX Therapeutics jumping above the current price in 90 days from now is about 64.97%. The CytomX Therapeutics probability density function shows the probability of CytomX Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.9581 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, CytomX Therapeutics will likely underperform. Additionally, cytomX Therapeutics has an alpha of 0.2079, implying that it can generate a 0.21 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of CytomX Therapeutics to move above the current price in 90 days from now is about 64.97 (This CytomX Therapeutics probability density function shows the probability of CytomX Stock to fall within a particular range of prices over 90 days) .
CytomX Stock Institutional Holders
Institutional Holdings refers to the ownership stake in CytomX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CytomX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CytomX Therapeutics' value.| Instituion | Recorded On | Shares | |
| Fmr Inc | 2023-12-31 | 565.3 K | |
| Bridgeway Capital Management, Llc | 2023-12-31 | 434.5 K | |
| Assenagon Asset Management Sa | 2023-12-31 | 404.7 K | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 363.3 K | |
| Formidable Asset Management Llc | 2023-12-31 | 306.1 K | |
| Tidal Investments Llc. | 2023-12-31 | 306.1 K | |
| State Street Corporation | 2023-12-31 | 267.5 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 266.8 K | |
| Congress Park Capital Llc | 2023-12-31 | 239.3 K | |
| Bvf Inc | 2023-09-30 | 6.6 M | |
| Tang Capital Management Llc | 2023-09-30 | 6.5 M |
CytomX Therapeutics Historical Income Statement
CytomX Therapeutics Income Statement is one of the three primary financial statements used for reporting CytomX's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of CytomX Therapeutics revenue and expense. CytomX Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, CytomX Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 86.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2 M in 2024. View More FundamentalsCytomX Stock Against Markets
Picking the right benchmark for CytomX Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in CytomX Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for CytomX Therapeutics is critical whether you are bullish or bearish towards CytomX Therapeutics at a given time. Please also check how CytomX Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in CytomX Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
CytomX Therapeutics Corporate Directors
CytomX Therapeutics corporate directors refer to members of a CytomX Therapeutics board of directors. The board of directors generally takes responsibility for the CytomX Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of CytomX Therapeutics' board members must vote for the resolution. The CytomX Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Matthew Young | Independent Director | Profile | |
| Charles Fuchs | Director | Profile | |
| Timothy Shannon | Independent Director | Profile | |
| John Scarlett | Director | Profile |
How to buy CytomX Stock?
Before investing in CytomX Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in CytomX Therapeutics. To buy CytomX Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of CytomX Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase CytomX Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located CytomX Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased CytomX Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as CytomX Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.
Already Invested in CytomX Therapeutics?
The danger of trading CytomX Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of CytomX Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than CytomX Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile CytomX Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether CytomX Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytomX Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomx Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomx Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.